EGFR and non-small cell lung carcinoma: Our group published the results of a phase II randomized clinical trial to compare the addition of metformin to TKI in comparison with TKI monotherapy in patients with NSCLC and EGFR mutations without a history or recent diagnosis of T2D; 139 patients were randomized, and the PFS, OS, ORR, and adverse events were evaluated.